Motif Neurotech activated the first site of its RESONATE study, opening enrollment at the University of Iowa. The early feasibility trial tests the DOT, a blueberry-sized wirelessly powered implant that sits in the skull above the brain without touching it, delivering stimulation to a region linked to depression. The study will expand to eight sites across six cities, evaluating safety over 12 months in patients with treatment-resistant depression. Motif positions the device as a durable alternative to repeated TMS sessions.

On May 1, Motif announced a multi-year semiconductor supply partnership with MintNeuro, securing purpose-built low-power neural interface chips for its DOT implant platform. The announcement followed Motif's late-April FDA clearance to begin RESONATE, its first clinical trial for treatment-resistant depression. Locking in a dedicated IC supply arrangement this early suggests the company is building toward pivotal scale. Motif's implant operates under strict power and size constraints that off-the-shelf components are not designed to meet.